- Motif Bio has presented new pre-clinical data regarding its investigational drug candidate iclaprim to the IDWeek 2017 conference in San Diego.

"The data presented today underscore the potential utility of iclaprim in a range of patient populations with suspected MRSA infections, including cystic fibrosis patients with Staphylococcus aureus lung infections," Motif Bio chief medical officer David Huang said.

At 8:16am: [LON:MTFB] Motif Bio Plc Ord 1p share price was +0.25p at 43.75p

Story provided by